Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Aug 17, 2018 12:26am

155 Views

Post# 28476040

RE:RE:RE:RE:RE:RE:No news

Edcando wrote: Lol so taking real market numbers of sales and using only 10% market share of one market out of 5 (and saying "if approved") and only saying if it traded at 1x sales (when most companies trade many more times sales than that) is called "dreaming"? Hahahaha get a grip. You must be a blast at parties with that shiny disposition .

You forgot to mention that in 12-18 months this project will be at the end of Phase II not going to market. That seems important.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale